Home|
Judge Blocks Anemia Drug Sales by an Amgen Rival A federal judge has tentatively barred Roche Holding from beginning sales in the United States of an anemia medication that a jury found violates patents held by Amgen. Home > Rss Directory > Business > NY Time |
|
Amgen's Anemia Drugs Ailing - Forbes dBTechnoAmgen's Anemia Drugs AilingForbes - 4 hours agoA new study said Amgen and Johnson & Johnson's anti-anemia treatments raise the risk of death via blood clots, but the news brings more problems for Amgen's ailing stock than for the much larger Johnson & Johnson. Home > Rss Directory > General > Google News |
|
Panel Seeks New Limits on Anemia Drugs - New York Times dBTechnoPanel Seeks New Limits on Anemia DrugsNew York Times - 1 hour agoBY ANDREW POLLACK A federal advisory panel, in response to mounting safety concerns, called on Thursday for additional restrictions on the use of anemia drugs by cancer patients.Amgen dodges b Home > Rss Directory > General > Google News |
|
Amgen Alters Anemia Drug Discounts The company is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product’s safety. Home > Rss Directory > Business > NY Time |
|
Amgen Draws Blood in Anemia-Drug War The pharmaceutical fights off rival Roche. Home > Rss Directory > General > Motley Fool |
|
FDA Reviewing Deaths in Anemia Drug Study - New York Times Enews 2.0FDA Reviewing Deaths in Anemia Drug StudyNew York Times - 20 hours agoBy REUTERS WASHINGTON (Reuters) - Federal health officials said Friday that they were reviewing a higher rate of deaths among patients treated with a Johnson & Johnson anemia drug in a Germa Home > Rss Directory > General > Google News |
|
UPDATE 1-Drug prevents bone loss in prostate cancer - Amgen - Reuters Ontario NowUPDATE 1-Drug prevents bone loss in prostate cancer - AmgenReuters - 3 hours agoBy Deena Beasley LOS ANGELES, July 14 (Reuters) - In a study, Amgen Inc's (AMGN.O: Quote, Profile, Research) experimental drug denosumab reduced the risk of osteoporosis and fract Home > Rss Directory > General > Google News |
|
F.D.A. to Tighten Use of Amgen Anemia Drugs The move, which the F.D.A. is expected to announce on Wednesday, represents the first time the agency has ordered changes in a drug’s prescribing information. Home > Rss Directory > General > NY Time |
|
F.D.A. to Tighten Use of Amgen Anemia Drugs The move, which the F.D.A. is expected to announce on Wednesday, represents the first time the agency has ordered changes in a drug’s prescribing information. Home > Rss Directory > Business > NY Time |
|
Study Finds Death Risk From Anemia Drugs Widely used anemia drugs sold by Amgen and Johnson & Johnson raise the risk of death among cancer patients by about 10 percent, a newly published analysis says. Home > Rss Directory > General > NY Time |
|
Study Finds Death Risk From Anemia Drugs Widely used anemia drugs sold by Amgen and Johnson & Johnson raise the risk of death among cancer patients by about 10 percent, a newly published analysis says. Home > Rss Directory > Business > NY Time |
|
Amgen Sells Drug Rights and Unit in Japan Biotechnology giant Amgen is selling the Japanese rights to some drugs to Takeda Pharmaceutical of Japan in a deal that might bring Amgen more than $1 billion. Home > Rss Directory > Business > NY Time |
|
Good Results for Amgen Bone Drug Buoys Stock Amgen’s experimental bone drug reduced the risk of spinal fractures in women with osteoporosis by 68 percent in a pivotal clinical trial. Home > Rss Directory > Business > NY Time |
|
Good Results for Bone Drug Buoy Amgen Amgen’s experimental bone drug reduced the risk of spinal fractures in women with osteoporosis by 68 percent in a pivotal clinical trial. Home > Rss Directory > Business > NY Time |
|
Panel Seeks New Limits on Anemia Drugs Yet both Amgen and Johnson & Johnson avoided the outcome they most feared: a recommendation that the drugs not be used by any cancer patients. Home > Rss Directory > General > NY Time |
|
Panel Seeks New Limits on Anemia Drugs Yet both Amgen and Johnson & Johnson avoided the outcome they most feared: a recommendation that the drugs not be used by any cancer patients. Home > Rss Directory > Business > NY Time |
|
Amgen earnings, sales beat forecast Biotech Amgen on Thursday reported an increase in earnings and a decrease in sales for the fourth quarter, beating Wall Street's forecast. Home > Rss Directory > Business > CNN |
|
Drug Companies Get Healthy, but at Whose Expense? News from Portfolio.com Also on Portfolio Esquire, E-Ink: Future of Print? Hollywood's Sudden Cash Crunch Even Conservatives Hate Michael Savage Subscribe to Portfolio magazine Trevor Foltz was six months old last fall, Home > Rss Directory > General > Wired News |
|
Drug Companies Get Healthy, but at Whose Expense? News from Portfolio.com Also on Portfolio Esquire, E-Ink: Future of Print? Hollywood's Sudden Cash Crunch Even Conservatives Hate Michael Savage Subscribe to Portfolio magazine Trevor Foltz was six months old last fall, Home > Rss Directory > Technology > Wired News |
|
Federal judge orders stop to Qualcomm chip sales A U.S. federal judge has clamped further restrictions on Qualcomm's ability to sell and support certain wireless chip sets, saying that they infringe on three patents held by rival Broadcom.The injunction, issue Home > Rss Directory > Technology > InfoWorld |